The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients
Matthew S. Davids(Harvard University), Andrew W. Roberts(The Royal Melbourne Hospital), Lori A. Gressick(AbbVie (United States)), Sari H. Enschede(AbbVie (United States)), Nikita Rudersdorf(AbbVie (United States)), Nicholas P. Montalvo(AbbVie (United States)), John M. Pagel(University of Washington), Rod Humerickhouse(Abbott Fund), Brad S. Kahl(UW Health University Hospital), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), John F. Seymour(The Royal Melbourne Hospital), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Jianning Yang(AbbVie (United States)), Elisa Cerri(AbbVie (United States)), Todd Busman(Abbott Fund), Martin Dunbar(AbbVie (United States))
Cited by 53
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k